Many MedTech companies are rethinking the house of brands model as portfolios become more complex through platforms, digital ecosystems, and long-term partnerships. A stronger masterbrand can help scale trust across the portfolio, simplify complexity, and support adoption of new technologies and services.

At Purdie Pascoe, we believe strong teams are built through shared experiences as well as everyday work. Our recent US team-building event in Orlando marked two years of our US office and reflected the progress, trust and momentum our close‑knit team has built together.

Webcast now available, featuring expert presenters Edward Nobrega, Principal Clinical Evaluation Scientist at Boston Scientific, Breda Kearney, Clinical Regulatory Lead at BSI, and Marcus Torr, Head of Post Market Surveys at Purdie Pascoe.

This article explores the role of post-market RWD/RWE in establishing sufficient clinical evidence for legacy devices transitioning to the MDR. It outlines key data sources, explains how off-label data can be captured and used, shares Notified Body perspectives and case study examples, and considers how post-market surveys can generate high-quality RWD. It concludes with practical guidance on integrating these data into an ongoing clinical evidence strategy.

Attending Quirk’s London, Paolo Gambetti and Michael Butler highlighted a shift in the AI narrative, with less emphasis on excitement and more on real-world value, responsibility and impact.

We are delighted to be attending DeviceTalks Boston from 27–28 May 2026. Kristy Beede, Research Director, and Nicole Levin, Associate Director, will be representing Purdie Pascoe at the event.

With 2026 marking the Regulatory Affairs Professionals Society’s 50th anniversary, the atmosphere felt especially energised. Between packed auditoriums, poster sessions, and many conversations, one thing became increasingly clear: post-market evidence generation is entering a far more mature and strategically important phase.

We are thrilled to announce that Marcus Torr, Head of Post Market Surveys at Purdie Pascoe, has been selected for the MedTech Leading Voice (MLV) list for a second year in a row. Marcus regularly shares his expertise at industry events and on LinkedIn. We are incredibly proud to see him featured in the prestigious MLV100 list. Don't miss his future insights by following him on LinkedIn.

In this webcast, our Precision Medicine and Diagnostics experts explore why true differentiation is often overlooked in real-world practice, and what diagnostic companies can do to ensure their tests and portfolios are clearly understood, valued and adopted.

The countdown is on for the 2026 Annual Meeting of the American Society of Clinical Oncology, taking place May 29 – June 2 in Chicago. Purdie Pascoe’s Precision Medicine and Diagnostics experts Marianne Fillion and Vanessa Slade will be attending and are looking forward to connecting with delegates at one of the world’s leading oncology events.

 Behind every great research project is a system quietly keeping thousands of data points accurate, scalable, and insight ready. In this article, our Programming & Analytics experts explore how automation and innovation are transforming large-scale market research, freeing researchers to focus on what matters most: delivering meaningful insight.

After attending the Society of American Gastrointestinal and Endoscopic Surgeons Conference up the road in sunny Tampa, FL, it was easy to see why this year’s theme, connect to purpose, was so fitting. Across lectures, panels, posters, and exhibits, a consistent narrative emerged: surgeons, KOLs, engineers, and medical device manufacturers are deeply aligned in a shared mission to improve patient outcomes and elevate provider experience.

After attending the American College of Cardiology (ACC) Conference 2026, Molly Hines and Supreet Kaur reflected on their key takeaways from the event. At ACC, much of the discussion was shaped by how artificial intelligence is increasingly being embedded into clinical practice, workflows, and healthcare systems.

In the third edition of our Precision Medicine & Diagnostics Newsletter, our team explores why primary care matters in Multi-Cancer Early Detection (MCED) and why its future hinges not just on innovation, but on integration.

We are delighted to be attending, sponsoring and presenting at the RAPS Euro Convergence from 5-8 April in Lisbon. Purdie Pascoe’s Post Market Survey experts Marcus Torr (Head of Post Market Surveys) Ellie Baker (Commercial Director) Alice Robertson (Research Manager) and Ruby Pogson Jones (Senior Research Executive ) are exhibiting on booth 31.

In this webcast our specialists Sabera Hyderally, Head of US MedTech and Kristin Lovallo, Director, will share how this advanced methodology can uncover deeper insights, helping organizations prioritize product features, refine value propositions, and make more confident strategic decisions.

Behavioural economics has long highlighted the importance of context. Data without context will only get you so far. MedTech companies need to understand why clinicians behave the way they do, how decisions actually get made inside hospitals, what ‘risk’ really means to different stakeholders and where friction exists within workflows, perceptions and emotions.

In the second edition of our Precision Medicine & Diagnostics Newsletter, our team explores the rise of early cancer detection through the lens of the consumer, covering growing interest in MCED, the shift toward proactive and direct-to-consumer testing, and the key awareness, perception, and education challenges shaping adoption.

We are delighted to be attending the ACC Annual Conference from March 28–30 in New Orleans, Louisiana. Senior Research Executives Molly Hines and Supreet Kaur will be representing Purdie Pascoe at the event.

We are delighted to be attending the SAGES Annual Conference from March 25–28 in Tampa, Florida. Kristin Lovallo, US Research Director, will be representing Purdie Pascoe at the event.